Grey Wolf Therapeutics Ltd. has identified phenyl-sulfamoyl-benzoic acid derivatives acting as endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors reported to be useful for the treatment of cancer, viral infection, inflammatory and immunological disorders.
